# An Open-label Phase II Study of Lorvotuzumab Mertansine

> **NCT02420873** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Lorvotuzumab Mertansine (IMGN901)

## Key facts

- **NCT ID:** NCT02420873
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-12
- **Primary completion:** 2017-06-06
- **Final completion:** 2017-06-06
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2018-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02420873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02420873, "An Open-label Phase II Study of Lorvotuzumab Mertansine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02420873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*